Stock 4169 TCM BIOTECH INTERNATIONAL CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings TCM Biotech International Corp.

Equities

4169

TW0004169008

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
55.7 TWD -0.36% Intraday chart for TCM Biotech International Corp. +10.08% -4.30%
Apr. 16 TCM Biotech International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 TCM Biotech International Corp. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company's enterprise value to sales, at 3.12 times its current sales, is high.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TCM BIOTECH INTERNATIONAL CORP. Stock TCM Biotech International Corp.
-4.30% 101M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.46% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4169 Stock
  4. Ratings TCM Biotech International Corp.